Argent BioPharma Limited (MGCLF)

0,2600 0,0000 (0,00%) Ab 10:34AM EDT. Markt geöffnet.

Argent BioPharma Limited

295 Rokeby Road
Suite 1
Subiaco, WA 6008
Australia
61 8 6555 2950
https://mgcpharma.com.au

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Roby Reuven Zomer	Co-Founder, CEO, MD & Executive Director	233,62k	N/A	1980
Mr. Tom Cairns	Chief Accounting Officer	N/A	N/A	N/A
Ms. Yifat Steuer	Deputy CEO & COO	N/A	N/A	N/A
Ms. Nicole Ann Godresse	Global Chief Sales Officer	N/A	N/A	N/A
Mr. Amir Polak	Chief Pharmaceutical Development Officer	N/A	N/A	N/A
Ms. Sabina Suljakovic	Head of the Quality Assurance Department	N/A	N/A	N/A
Dr. Nadya Lisovoder	Chief Medical Officer	N/A	N/A	N/A
Ms. Sasha Friedman	Deputy CEO	N/A	N/A	N/A
Yair Tal	Chief Information Security Officer	N/A	N/A	N/A
Mr. Robert Clements	Chief Commercial Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer. The company was formerly known as MGC Pharmaceuticals Limited and changed it name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.

Corporate Governance

Argent BioPharma Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.